Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

L. Herrera; C. Stanciu-Herrera; C. Morgan; V. Ghetie; E. S. Vitetta

doi:10.1080/10428190600821989

Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

L. Herrera, C. Stanciu-Herrera, C. Morgan, V. Ghetie, E. S. Vitetta

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

Original language	English (US)
Pages (from-to)	2380-2387
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	47
Issue number	11
DOIs	https://doi.org/10.1080/10428190600821989
State	Published - Nov 2006

Keywords

Chemotherapy
Childhood leukemia
Immunotherapy
Immunotoxins
Monoclonal antibodies
Pre-B ALL

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428190600821989

Cite this

@article{f693f0a85e694dda916e57f3e0944970,

title = "Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia",

abstract = "The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.",

keywords = "Chemotherapy, Childhood leukemia, Immunotherapy, Immunotoxins, Monoclonal antibodies, Pre-B ALL",

author = "L. Herrera and C. Stanciu-Herrera and C. Morgan and V. Ghetie and Vitetta, {E. S.}",

note = "Funding Information: This study was supported by Temple University Children{\textquoteright}s Medical Center, Scott & White Hospital New Programs Initiative, the Cancer Immunobiology Center, and a generous gift from Mr Wayne Hughes.",

year = "2006",

month = nov,

doi = "10.1080/10428190600821989",

language = "English (US)",

volume = "47",

pages = "2380--2387",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

AU - Herrera, L.

AU - Stanciu-Herrera, C.

AU - Morgan, C.

AU - Ghetie, V.

AU - Vitetta, E. S.

N1 - Funding Information: This study was supported by Temple University Children’s Medical Center, Scott & White Hospital New Programs Initiative, the Cancer Immunobiology Center, and a generous gift from Mr Wayne Hughes.

PY - 2006/11

Y1 - 2006/11

N2 - The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

AB - The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

KW - Chemotherapy

KW - Childhood leukemia

KW - Immunotherapy

KW - Immunotoxins

KW - Monoclonal antibodies

KW - Pre-B ALL

UR - http://www.scopus.com/inward/record.url?scp=33751101580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751101580&partnerID=8YFLogxK

U2 - 10.1080/10428190600821989

DO - 10.1080/10428190600821989

M3 - Article

C2 - 17107913

AN - SCOPUS:33751101580

SN - 1042-8194

VL - 47

SP - 2380

EP - 2387

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this